Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $72.86M |
| Net Income (Most Recent Fiscal Year) | $-218.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.89 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -342.73% |
| Net Margin (Trailing 12 Months) | -344.95% |
| Return on Equity (Trailing 12 Months) | -35.74% |
| Return on Assets (Trailing 12 Months) | -29.54% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.66 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.66 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.95 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.87 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.16 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.15 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 69.71M |
| Free Float | 53.74M |
| Market Capitalization | $310.20M |
| Average Volume (Last 20 Days) | 0.38M |
| Beta (Past 60 Months) | 1.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.15% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |